At Reuters Pharma USA in March, ZS Associates' Maria Whitman sat down with pharmaphorum to discuss why it's time to reinvent pharma's marketing strategy
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh